References
1. Schulkes KJG, Van den Elzen MT, Hack EC, Otten HG, Bruijnzeel-Koomen
C, Knulst AC. Clinical similarities among bradykinin-mediated and mast
cell-mediated subtypes of non-hereditary angioedema: a retrospective
study. Clin Transl Allergy. 2015;5(1):5.
2. Zuberbier T, Abdul Latiff AH, Abuzakouk M, Aquilina S, Asero R, Baker
D, et al. The International EAACI/GA(2)LEN/EuroGuiDerm/APAAACI Guideline
for the Definition, Classification, Diagnosis and Management of
Urticaria. Allergy. 2021.
3. Alizadeh Aghdam M, Knol EF, van den Elzen M, den Hartog Jager C, van
Os-Medendorp H, Knulst AC, et al. Response of FcepsilonRI-bearing
leucocytes to omalizumab in chronic spontaneous urticaria. Clin Exp
Allergy. 2020.
4. Busse PJ, Christiansen SC. Hereditary Angioedema. N Engl J Med.
2020;382(12):1136-48.
5. Cicardi M, Zuraw BL. Angioedema Due to Bradykinin Dysregulation. J
Allergy Clin Immunol Pract. 2018;6(4):1132-41.
6. Zingale LC, Beltrami L, Zanichelli A, Maggioni L, Pappalardo E,
Cicardi B, et al. Angioedema without urticaria: a large clinical survey.
CMAJ. 2006;175(9):1065-70.
7. Mansi M, Zanichelli A, Coerezza A, Suffritti C, Wu MA, Vacchini R, et
al. Presentation, diagnosis and treatment of angioedema without wheals:
a retrospective analysis of a cohort of 1058 patients. J Intern Med.
2015;277(5):585-93.
8. Hofman ZLM, van West N, Hack CE, Knulst AC, Maas C, Rockmann H. High
occurrence of antihistamine resistance in patients with recurrent
idiopathic angioedema. Clin Transl Allergy. 2019;9:35.
9. Cicardi M, Aberer W, Banerji A, Bas M, Bernstein JA, Bork K, et al.
Classification, diagnosis, and approach to treatment for angioedema:
consensus report from the Hereditary Angioedema International Working
Group. Allergy. 2014;69(5):602-16.
10. Cugno M, Tedeschi A, Nussberger J. Bradykinin in idiopathic
non-histaminergic angioedema. Clin Exp Allergy. 2017;47(1):139-40.
11. Porebski G, Kwitniewski M, Reshef A. Biomarkers in Hereditary
Angioedema. Clin Rev Allergy Immunol. 2021;60(3):404-15.
12. Reshef A, Zanichelli A, Longhurst H, Relan A, Hack CE. Elevated
D-dimers in attacks of hereditary angioedema are not associated with
increased thrombotic risk. Allergy. 2015;70(5):506-13.
13. Asero R. D-dimer: a biomarker for antihistamine-resistant chronic
urticaria. J Allergy Clin Immunol. 2013;132(4):983-6.
14. Zuraw BL. Clinical practice. Hereditary angioedema. N Engl J Med.
2008;359(10):1027-36.
15. Zuraw BL, Cicardi M, Longhurst HJ, Bernstein JA, Li HH, Magerl M, et
al. Phase II study results of a replacement therapy for hereditary
angioedema with subcutaneous C1-inhibitor concentrate. Allergy.
2015;70(10):1319-28.
16. Gravante C, Carucci L, Bova M, Petraroli A, Genovese A, Marone G.
Prophylactic treatment with plasma-derived C1 inhibitor in idiopathic
non-histaminergic angioedema. Pediatr Allergy Immunol. 2016;27(6):658-9.
17. Shroba J, Hanson J, Portnoy J. Current treatment options for
idiopathic angioedema. Ann Allergy Asthma Immunol. 2015;115(5):429-33.
18. Stahl MC, Harris CK, Matto S, Bernstein JA. Idiopathic
nonhistaminergic angioedema successfully treated with ecallantide,
icatibant, and C1 esterase inhibitor replacement. J Allergy Clin Immunol
Pract. 2014;2(6):818-9.
19. Weller K, Groffik A, Magerl M, Tohme N, Martus P, Krause K, et al.
Development, validation, and initial results of the Angioedema Activity
Score. Allergy. 2013;68(9):1185-92.
20. Weller K, Groffik A, Magerl M, Tohme N, Martus P, Krause K, et al.
Development and construct validation of the angioedema quality of life
questionnaire. Allergy. 2012;67(10):1289-98.
21. Kulthanan K, Chularojanamontri L, Rujitharanawong C, Weerasubpong P,
Maurer M, Weller K. Angioedema quality of life questionnaire (AE-QoL) -
interpretability and sensitivity to change. Health Qual Life Outcomes.
2019;17(1):160.
22. Hofman ZLM, de Maat S, Suffritti C, Zanichelli A, van Doorn C,
Sebastian SAE, et al. Cleaved kininogen as a biomarker for bradykinin
release in hereditary angioedema. J Allergy Clin Immunol.
2017;140(6):1700-3 e8.
23. Bernstein JA, Relan A, Harper JR, Riedl M. Sustained response of
recombinant human C1 esterase inhibitor for acute treatment of
hereditary angioedema attacks. Ann Allergy Asthma Immunol.
2017;118(4):452-5.
24. Schousboe I. Binding of activated Factor XII to endothelial cells
affects its inactivation by the C1-esterase inhibitor. Eur J Biochem.
2003;270(1):111-8.
25. Hack CE, Relan A, van Amersfoort ES, Cicardi M. Target levels of
functional C1-inhibitor in hereditary angioedema. Allergy.
2012;67(1):123-30.
26. Farrell C, Hayes S, Relan A, van Amersfoort ES, Pijpstra R, Hack CE.
Population pharmacokinetics of recombinant human C1 inhibitor in
patients with hereditary angioedema. Br J Clin Pharmacol.
2013;76(6):897-907.
27. Zuraw BL, Busse PJ, White M, Jacobs J, Lumry W, Baker J, et al.
Nanofiltered C1 inhibitor concentrate for treatment of hereditary
angioedema. N Engl J Med. 2010;363(6):513-22.
28. Pawaskar D, Tortorici MA, Zuraw B, Craig T, Cicardi M, Longhurst H,
et al. Population pharmacokinetics of subcutaneous C1-inhibitor for
prevention of attacks in patients with hereditary angioedema. Clin Exp
Allergy. 2018;48(10):1325-32.
29. Longhurst H, Farkas H. Biological therapy in hereditary angioedema:
transformation of a rare disease. Expert Opin Biol Ther.
2020;20(5):493-501.
30. Valerieva A, Staevska MT, Grivcheva-Panovska V, Jesenak M, Kohalmi
KV, Hrubiskova K, et al. Recombinant human C1 esterase inhibitor for
hereditary angioedema attacks: A European registry. World Allergy Organ
J. 2021;14(4):100535.
31. Bucher MC, Petkovic T, Helbling A, Steiner UC. Idiopathic
non-histaminergic acquired angioedema: a case series and discussion of
published clinical trials. Clin Transl Allergy. 2017;7:27.
32. Belbezier A, Bocquet A, Bouillet L. Idiopathic Angioedema: Current
Challenges. J Asthma Allergy. 2020;13:137-44.
33. Sala-Cunill A, Bjorkqvist J, Senter R, Guilarte M, Cardona V,
Labrador M, et al. Plasma contact system activation drives anaphylaxis
in severe mast cell-mediated allergic reactions. J Allergy Clin Immunol.
2015;135(4):1031-43 e6.